* Alimera Sciences Inc ALIM.OQ ALIM.O is expected
to show a
rise in quarterly revenue when it reports results on July 25
(estimated).
* The Alpharetta Georgia-based company is expected to
report a
40.1% increase in revenue to $20.462 million from $14.6 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Alimera Sciences
Inc is
for earnings of 1 cent per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Alimera
Sciences
Inc is $8, above its last closing price of $3.66.
This summary was machine generated July 21 at 13:43 GMT. All
figures in US dollars unless otherwise stated